Tag: NIH

J&J shot performs best with paired with booster dose from Moderna or Pfizer, NIH study suggests

FILE PHOTO: Vials of coronavirus disease (COVID-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny/File Photo/File Photo/File Photo(Reuters) -People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from

NIH ACTIV working group weighs human challenge studies for SARS-CoV-2 vaccine development

In a Perspective for the New England Journal of Medicine, members of the National Institutes of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for human challenge studies, to support SARS-CoV-2 vaccine development. In the article,

NIH begins clinical trial of live, attenuated Zika vaccine

Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial will enroll a total of 28 healthy, non-pregnant adults ages 18 to 50 at the Johns Hopkins Bloomberg

NIH warns of increased risk of heat-related illness for seniors

(HealthDay)—Older adults are at significantly increased risk of heat-related illnesses, which can include heat stroke, heat edema, heat syncope, heat cramps, and heat exhaustion, according to the National Institutes of Health. Factors that could increase risk include age-related changes to the skin such as poor blood circulation and inefficient sweat glands; heart, lung, and kidney